CD8A and melanoma: Another recent phase I study has demonstrated that intratumoral injection of IFNα-differentiated unloaded autologous DC 1 day following dacarbazine treatment is associated with induction of tumor-specific CD8+ T cell responses and stabilization of disease in a small cohort of stage IV melanoma patients (75).